Display Settings:

Format

Send to:

Choose Destination
    J Clin Invest. 2007 Mar;117(3):568-75.

    ECM remodeling in hypertensive heart disease.

    Source

    Cardiovascular Research Institute and Department of Medicine, University of Rochester, Rochester, NY 14642, USA. bradford_berk@urmc.rochester.edu

    Abstract

    Hypertensive heart disease (HHD) occurs in patients that clinically have both diastolic and systolic heart failure and will soon become the most common cause of heart failure. Two key aspects of heart failure secondary to HHD are the relatively highly prevalent LV hypertrophy and cardiac fibrosis, caused by changes in the local and systemic neurohormonal environment. The fibrotic state is marked by changes in the balance between MMPs and their inhibitors, which alter the composition of the ECM. Importantly, the fibrotic ECM impairs cardiomyocyte function. Recent research suggests that therapies targeting the expression, synthesis, or activation of the enzymes responsible for ECM homeostasis might represent novel opportunities to modify the natural progression of HHD.

    PMID:
    17332884
    [PubMed - indexed for MEDLINE]
    PMCID: PMC1804378
    Free PMC Article

    Images from this publication.See all images (5) Free text

    Figure 3
    Figure 2
    Figure 1
    Figure 5
    Figure 4

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk